Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma

Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX51107, in solid cancer patients, liver metastases of uveal melan...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EMBO Mol Med
Asıl Yazarlar: Chua, Vivian, Orloff, Marlana, Teh, Jessica LF, Sugase, Takahito, Liao, Connie, Purwin, Timothy J, Lam, Bao Q, Terai, Mizue, Ambrosini, Grazia, Carvajal, Richard D, Schwartz, Gary, Sato, Takami, Aplin, Andrew E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6365926/
https://ncbi.nlm.nih.gov/pubmed/30610113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201809081
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller